Compare Adaptive Biotechnologies Corp (ADPT) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Newegg Commerce Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Newegg Commerce Inc trades at $14.31 (market cap $314.92M). The key difference: Adaptive Biotechnologies Corp is far larger — about 10.6× Newegg Commerce Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | NEGG | |
|---|---|---|
Market Cap | $3.33B | $314.92M |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $128.09 |
52-Week Low | $10.24 | $14.72 |
Enterprise Value | $3.19B | $313.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
NEGG trades at $14.94 with minimal daily movement (+0.2%). The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment. Recent financials reveal modest revenue growth to $1.44B in 2025, though profitability remains challenged with a net loss of $4.88M. The company is investing in AI shopping experiences and promotional events to drive growth.
While analyst consensus is bullish (100% buy rating), fundamental weaknesses including negative cash flow from operations and thin margins present risks. The stock's valuation appears stretched with a P/E of 57.14, suggesting limited near-term upside without significant earnings improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
